What is the total authorization amount for MaxCyte's share repurchase program?

MaxCyte's Board authorized a $10 million share repurchase program. As of the filing date (August 12, 2026), the company has repurchased approximately $5.5 million, leaving approximately $4.5 million remaining under the authorization.

How much has MaxCyte actually repurchased under this program to date?

MaxCyte has repurchased approximately $5.5 million of common stock to date. The company's cash flow statement shows $1.478 million in repurchases during the six-month period ended June 30, 2026, and the balance sheet reflects 1,313,066 shares held as treasury stock.

What execution method does MaxCyte use for its share repurchases?

The filing does not specify whether repurchases are executed via Rule 10b-18 open-market purchases, a 10b5-1 plan, accelerated share repurchase, or another method. This detail is not disclosed in the earnings announcement or accompanying financial statements.

How does the share repurchase program fit within MaxCyte's capital allocation strategy?

MaxCyte noted in its guidance that it expects to end 2026 with at least $130.5 million in cash, cash equivalents, and investments, excluding any further share repurchase deployments. This signals the company is balancing capital returns with preservation of liquidity amid near-term revenue headwinds.

Why is MaxCyte conducting share repurchases while facing revenue declines?

Q2 2026 core revenue declined 21% year-over-year; however, the company achieved a significant reduction in net loss and recently signed a multi-platform technology license partnership with Genentech. Management appears to view share repurchases as opportunistic capital deployment given the company's solid cash position and expectations for future growth drivers.

What is the impact on shares outstanding from the repurchase program so far?

As of June 30, 2026, MaxCyte had 106,134,011 shares outstanding (down from 106,789,618 at year-end 2025) and 1,313,066 treasury shares. The repurchases have modestly reduced dilution, though the full share-count impact will depend on the pace of remaining buybacks.

MXCT 8-K Filed 2026-08-12 Execution disclosure

MaxCyte repurchased $5.5M stock under $10M authorization

Cell-engineering company executes on share buyback program; $1.5M repurchased in H1 2026, $4.8M remaining</anhead> <parameter name="authorization_amount_usd">10000000

Remaining$4M

MechanismNot specified

What the filing says

MaxCyte, Inc. (NASDAQ: MXCT), a cell-engineering company focused on platform technologies for cell therapeutics, reported in its second-quarter 2026 earnings announcement that it has repurchased approximately $5.5 million of common stock to date under a $10 million share repurchase program authorized by the Board. This leaves approximately $4.5 million remaining under the authorization.

The company's cash flow statement for the six months ended June 30, 2026 shows total repurchases of common stock of $1.478 million during the period, with corresponding treasury stock recorded at cost. As of June 30, 2026, MaxCyte held 1,313,066 treasury shares. The company ended the quarter with total cash, cash equivalents, and investments of $141.9 million.

In its forward-looking guidance, MaxCyte noted that it expects to end 2026 with at least $130.5 million in total cash, cash equivalents and investments, excluding any further capital deployed toward the share repurchase program. The specific mechanics of execution under the repurchase authorization—whether Rule 10b-18 open-market purchases, 10b5-1 plan, or other method—are not disclosed in this filing.

Repurchased approximately $5.5 million of common stock to date under the Company's $10 million share repurchase program authorized by the Board — MAXCYTE, INC. 8-K filing · View on SEC EDGAR →

What this means

MaxCyte's $10 million share repurchase authorization represents a modest capital return program relative to its $141.9 million cash position as of mid-2026. With $5.5 million deployed to date, the company retains flexibility on the timing and pace of remaining repurchases. The filing indicates management views the stock as an appropriate use of capital alongside operational investments in a company navigating revenue challenges—Q2 2026 core revenue declined 21% year-over-year—but with recent strategic milestones including a Genentech partnership and growing royalty revenue from its Strategic Platform License portfolio. The remaining authorization offers optionality without imposing mandatory deployment.

Frequently asked questions

What is the total authorization amount for MaxCyte's share repurchase program?: MaxCyte's Board authorized a $10 million share repurchase program. As of the filing date (August 12, 2026), the company has repurchased approximately $5.5 million, leaving approximately $4.5 million remaining under the authorization.
How much has MaxCyte actually repurchased under this program to date?: MaxCyte has repurchased approximately $5.5 million of common stock to date. The company's cash flow statement shows $1.478 million in repurchases during the six-month period ended June 30, 2026, and the balance sheet reflects 1,313,066 shares held as treasury stock.
What execution method does MaxCyte use for its share repurchases?: The filing does not specify whether repurchases are executed via Rule 10b-18 open-market purchases, a 10b5-1 plan, accelerated share repurchase, or another method. This detail is not disclosed in the earnings announcement or accompanying financial statements.
How does the share repurchase program fit within MaxCyte's capital allocation strategy?: MaxCyte noted in its guidance that it expects to end 2026 with at least $130.5 million in cash, cash equivalents, and investments, excluding any further share repurchase deployments. This signals the company is balancing capital returns with preservation of liquidity amid near-term revenue headwinds.
Why is MaxCyte conducting share repurchases while facing revenue declines?: Q2 2026 core revenue declined 21% year-over-year; however, the company achieved a significant reduction in net loss and recently signed a multi-platform technology license partnership with Genentech. Management appears to view share repurchases as opportunistic capital deployment given the company's solid cash position and expectations for future growth drivers.
What is the impact on shares outstanding from the repurchase program so far?: As of June 30, 2026, MaxCyte had 106,134,011 shares outstanding (down from 106,789,618 at year-end 2025) and 1,313,066 treasury shares. The repurchases have modestly reduced dilution, though the full share-count impact will depend on the pace of remaining buybacks.

execution authorization mid-cap biotech-sector cash-generative

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.